ALDX - Aldeyra The

https://www.aldeyra.com

Buy Momentum: Bearish

Recent News

Aldeyra Therapeutics ( ALDX ) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks Commentary • 2 months ago • score: 0.41

Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Bullish

Are Medical Stocks Lagging Amgen ( AMGN ) This Year?

Zacks Commentary • 2 months ago • score: 0.38

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.

52W High

$7.20

52W Low

$1.14

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.79

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.50

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

6.04

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

3.10%

Institutions (25–75% balanced)

57.59%

Shares Outstanding

60,046,000

Float

48,481,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.85

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.66%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1285

0.1518

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025